Payment overview · 2025
General Payments
$305.49
13 reported records · 9 companies
Healthcare provider profile · identity verified
John B Hylton, MD
Allopathic & Osteopathic Physicians|Internal Medicine · COOPER CITY, FL · NPI 1316951700
Verified facts
What the public records show
CMS Open Payments records show John B Hylton, MD received $305.49 in general payments during 2025 across 13 reported records.
Lilly USA, LLC accounted for 17.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Mounjaro, Ozempic, Paxlovid.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 57 claims for Mounjaro by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 120 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $54.60 | 17.9% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $54.14 | 17.7% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $44.68 | 14.6% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $32.67 | 10.7% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $28.76 | 9.4% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $26.58 | 8.7% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $25.51 | 8.3% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $20.00 | 6.5% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $18.55 | 6.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $273.22 | 12 |
| Education | $32.27 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $54.60 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $32.67 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $28.76 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $26.58 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $26.50 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $26.50 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $25.51 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $21.87 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE Normalized: freestyle libre |
Device | Abbott Laboratories | $20.00 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $18.55 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $18.55 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $18.18 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $17.44 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 120 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 28 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 57 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 54 | exact normalized | Medicare Part D |
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 11 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
28 | 13 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
28 | 13 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
57 | 12 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
54 | 12 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
120 | 29 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
11 | 11 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 855 | 257 |
| Amlodipine Besylate | Amlodipine Besylate | 837 | 236 |
| Losartan Potassium | Losartan Potassium | 517 | 149 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 485 | 158 |
| Metformin Hcl | Metformin Hcl | 476 | 131 |
| Lisinopril | Lisinopril | 415 | 121 |
| Levothyroxine Sodium | Levothyroxine Sodium | 382 | 97 |
| Alprazolam | Alprazolam | 331 | 59 |
| Simvastatin | Simvastatin | 309 | 83 |
| Metoprolol Tartrate | Metoprolol Tartrate | 249 | 71 |
| Metoprolol Succinate | Metoprolol Succinate | 246 | 69 |
| Tamsulosin Hcl | Tamsulosin Hcl | 238 | 67 |
| Hydrochlorothiazide | Hydrochlorothiazide | 234 | 63 |
| Omeprazole | Omeprazole | 230 | 72 |
| Gabapentin | Gabapentin | 177 | 67 |
| Pioglitazone Hcl | Pioglitazone Hcl | 174 | 47 |
| Pantoprazole Sodium | Pantoprazole Sodium | 168 | 55 |
| Pravastatin Sodium | Pravastatin Sodium | 164 | 44 |
| Zolpidem Tartrate | Zolpidem Tartrate | 154 | 23 |
| Nifedipine Er | Nifedipine | 144 | 40 |
| Sertraline Hcl | Sertraline Hcl | 144 | 42 |
| Ramipril | Ramipril | 138 | 34 |
| Clopidogrel | Clopidogrel Bisulfate | 124 | 29 |
| Carvedilol | Carvedilol | 123 | 32 |
| Ezetimibe | Ezetimibe | 123 | 44 |
| Eliquis | Apixaban | 120 | 29 |
| Terazosin Hcl | Terazosin Hcl | 119 | 33 |
| Furosemide | Furosemide | 116 | 46 |
| Finasteride | Finasteride | 115 | 30 |
| Atenolol | Atenolol | 114 | 31 |
| Glimepiride | Glimepiride | 114 | 32 |
| Tramadol Hcl | Tramadol Hcl | 108 | 36 |
| Glipizide | Glipizide | 105 | 31 |
| Temazepam | Temazepam | 104 | 14 |
| Trazodone Hcl | Trazodone Hcl | 94 | 23 |
| Meloxicam | Meloxicam | 89 | 28 |
| Allopurinol | Allopurinol | 87 | 29 |
| Fenofibrate | Fenofibrate | 85 | 25 |
| Hydralazine Hcl | Hydralazine Hcl | 82 | 20 |
| Alendronate Sodium | Alendronate Sodium | 79 | 23 |
| Montelukast Sodium | Montelukast Sodium | 76 | 28 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 71 | 20 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 70 | 19 |
| Paroxetine Hcl | Paroxetine Hcl | 69 | 16 |
| Donepezil Hcl | Donepezil Hcl | 68 | 20 |
| Fluticasone Propionate | Fluticasone Propionate | 68 | 28 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 62 | 32 |
| Azithromycin | Azithromycin | 62 | 55 |
| Lorazepam | Lorazepam | 61 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 61 | 19 |
| Quetiapine Fumarate | Quetiapine Fumarate | 61 | 13 |
| Sildenafil Citrate | Sildenafil Citrate | 60 | 14 |
| Benazepril Hcl | Benazepril Hcl | 59 | 18 |
| Mounjaro | Tirzepatide | 57 | 12 |
| Clonazepam | Clonazepam | 56 | suppressed |
| Ibuprofen | Ibuprofen | 56 | 24 |
| Naproxen | Naproxen | 56 | 22 |
| Xarelto | Rivaroxaban | 56 | 13 |
| Ozempic | Semaglutide | 54 | 12 |
| Potassium Chloride | Potassium Chloride | 51 | 18 |
| Fluoxetine Hcl | Fluoxetine Hcl | 50 | 14 |
| Doxazosin Mesylate | Doxazosin Mesylate | 48 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 48 | 14 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 48 | 17 |
| Pregabalin | Pregabalin | 47 | 12 |
| Famotidine | Famotidine | 45 | 12 |
| Escitalopram Oxalate | Escitalopram Oxalate | 43 | 12 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 42 | 12 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 38 | 22 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 37 | 29 |
| Dicyclomine Hcl | Dicyclomine Hcl | 37 | 18 |
| Lovastatin | Lovastatin | 37 | 11 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 36 | 26 |
| Prednisone | Prednisone | 35 | 16 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 35 | 30 |
| Synthroid | Levothyroxine Sodium | 35 | suppressed |
| Bupropion Xl | Bupropion Hcl | 34 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 34 | 13 |
| Fluconazole | Fluconazole | 33 | 26 |
| Methylprednisolone | Methylprednisolone | 32 | 30 |
| Breo Ellipta | Fluticasone/Vilanterol | 31 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 30 | 11 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 30 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 29 | suppressed |
| Spironolactone | Spironolactone | 29 | suppressed |
| Valsartan | Valsartan | 29 | 12 |
| Jardiance | Empagliflozin | 28 | 13 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 28 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 26 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 26 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 25 | 13 |
| Januvia | Sitagliptin Phosphate | 25 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 25 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 25 | 16 |
| Novolog Mix 70-30 | Insulin Aspart Prot/Insuln Asp | 23 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 23 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 22 | 19 |
| Diazepam | Diazepam | 21 | suppressed |
| Entresto | Sacubitril/Valsartan | 21 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 21 | suppressed |
| Memantine Hcl | Memantine Hcl | 21 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 20 | suppressed |
| Myrbetriq | Mirabegron | 20 | suppressed |
| Risperidone | Risperidone | 20 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 20 | suppressed |
| Levetiracetam | Levetiracetam | 19 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 19 | suppressed |
| Amoxicillin | Amoxicillin | 18 | 18 |
| Clonidine Hcl | Clonidine Hcl | 18 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 18 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 18 | suppressed |
| Baclofen | Baclofen | 17 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 17 | suppressed |
| Imipramine Hcl | Imipramine Hcl | 17 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Novolog Flexpen | Insulin Aspart | 17 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 16 | suppressed |
| Bumetanide | Bumetanide | 16 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 16 | suppressed |
| Celecoxib | Celecoxib | 15 | suppressed |
| Irbesartan | Irbesartan | 15 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Linzess | Linaclotide | 15 | suppressed |
| Methimazole | Methimazole | 15 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Torsemide | Torsemide | 15 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 15 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 14 | suppressed |
| Chlorthalidone | Chlorthalidone | 14 | suppressed |
| Indapamide | Indapamide | 14 | suppressed |
| Mupirocin | Mupirocin | 14 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 14 | suppressed |
| Armour Thyroid | Thyroid,pork | 13 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 13 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 13 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 13 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 12 | suppressed |
| Estradiol | Estradiol | 12 | suppressed |
| Sotalol | Sotalol Hcl | 12 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 12 | suppressed |
| Dilantin | Phenytoin Sodium Extended | 11 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 11 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 11 | suppressed |
| Hydrocortisone | Hydrocortisone | 11 | suppressed |
| Jantoven | Warfarin Sodium | 11 | suppressed |
| Latanoprost | Latanoprost | 11 | suppressed |
| Mirtazapine | Mirtazapine | 11 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 11 | 11 |
| Rybelsus | Semaglutide | 11 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 11 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $305.49 · 13 records | Lilly USA, LLC | AREXVY, Cologuard Collection Kit, Dexcom G6 Transmitter, ELIQUIS, FREESTYLE LIBRE, JARDIANCE, LEQVIO, MOUNJARO, NURTEC ODT, Ozempic, PAXLOVID, SHINGRIX, ZEPBOUND | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Boehringer Ingelheim Pharmaceuticals, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error